- Human pathology

Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > bortezomib


Sunday 5 June 2005


Bortezomib (INN, PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans.

It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma.

In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.


- Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. PNAS, 2012.

See also

- proteasome inhibitors


- Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer.Cancer Res. 2004 Aug 1;64(15):5036-43. PMID: 15289299